Welcome to our dedicated page for Currenc Group news (Ticker: CURR), a resource for investors and traders seeking the latest updates and insights on Currenc Group stock.
Currenc Group Inc. (Nasdaq: CURR) regularly issues news updates that describe its activities as a fintech company focused on artificial intelligence (AI) solutions for financial institutions and digital remittance services. Its press releases cover both operational developments and corporate transactions, providing context for investors and other readers who follow CURR news.
Readers of this news feed can expect coverage of financial results, including quarterly and half-year reports that discuss Total Processing Value (TPV) through Tranglo, remittance revenues, airtime revenues, gross margin and EBITDA. These releases often include management commentary on remittance performance, shifts away from lower-margin airtime transfers and the expansion of AI initiatives.
Currenc’s news also highlights strategic and capital-structure actions. Examples in the supplied disclosures include a proposed reverse merger with Animoca Brands Corporation Limited, a definitive agreement to divest its 60% controlling interest in Tranglo to New Margin Holding Limited, convertible note financings with warrants, and a shares-for-debt transaction in which related party loans were converted into equity. Such announcements describe how the company intends to reshape its business mix, reduce debt and support AI, Web3 and digital assets initiatives.
Additional news items address governance and leadership, such as CEO transitions and amendments to executive employment agreements, as well as steps the company has taken to monitor potential naked short selling in its stock. Together, these categories of news provide insight into how Currenc presents its operational performance, strategic direction and shareholder-related actions over time.
Investors and observers who follow CURR news can use this stream of press releases to track updates on remittance operations, AI product development, proposed corporate combinations and financing arrangements as described directly by the company in its public communications.
On August 3, 2022, CURE Pharmaceutical Holding Corp. (OTC: CURR) hosted a shareholder call to discuss a recent $20 million non-dilutive sale of part of its product and intellectual property portfolio. The executive team outlined their strategy to innovate and monetize their technology while building The Sera Labs brands to enhance shareholder value. The call's replay will be available until August 3, 2023. CURE is known for its patented drug delivery platform, CUREform™, which aims to improve drug efficacy and patient experience.
CURE Pharmaceutical has appointed Gerald Bagg to its board of directors, enhancing its expertise in the consumer packaged goods (CPG) and advertising sectors. Bagg, a 45-year veteran in advertising, aims to leverage his experience to bolster the company's branding efforts and drive growth for its subsidiary, The Sera Labs, Inc., which focuses on wellness and beauty products. This move increases the board's membership to five, aligning with CURE's strategy to develop and acquire innovative brands.
CURE Pharmaceutical Holding Corp. (OTC: CURR) announces a teleconference on August 3, 2022, to discuss a recent $20 million non-dilutive sale of part of its product and IP portfolio. The company retains exclusive rights to its Nutraceutical Nutri-Strip products and is pursuing international transactions to monetize its extensive patent portfolio, which includes areas like CBD and psychedelics. CURE's subsidiary, The Sera Labs, plans to relaunch its Seratopical Revolution line, recently supplied to over 1,200 Walmart stores, as part of its strategy to enhance shareholder value.
CURE Pharmaceutical Holding Corp. (OTC: CURR) announced the sale of part of its intellectual property for $20 million. This transaction allows CURE to reduce debt and invest in its wellness and beauty brands. The company retains its proprietary platform technology, which it plans to monetize further. A conference call is scheduled for August 3, 2022, to update shareholders. CURE develops patented drug delivery systems and operates an FDA-registered facility, partnering with various health and beauty sectors globally.
CURE Pharmaceutical Holdings (OTC: CURR) announced that its OTF Vitamin D, branded as ImmunD3™ Nutri-Strips™, outperformed standard supplementation in achieving vitamin D sufficiency in pediatric patients undergoing stem cell therapy. Conducted at Cincinnati Children’s Hospital Medical Center (CCHMC), the study demonstrated significant improvements in vitamin D levels, enhancing patient outcomes and reducing complications. CCHMC aims to include this innovative supplement in its formulary, with plans for broader adoption in children’s hospitals nationwide.
CURE Pharmaceutical Holding Corp. (OTC: CURR) announced that its subsidiary, Sera Labs, will launch the Seratopical Revolution skincare line in Walmart, CVS, and Bed Bath & Beyond stores. Additionally, the Nutri-Strips™ oral thin film, leveraging proprietary technology, will be available at CVS and Target.com. CEO Nancy Duitch emphasized the brand's competitive edge through advanced delivery systems and partnerships, including a collaboration with actress Nicole Kidman. The innovative skincare line combines plant-based ingredients with a unique delivery system for improved efficacy.
COFEPRIS, Mexico's FDA equivalent, has approved CURE Pharmaceutical's products for manufacture and sale in Mexico. This includes the innovative CUREform™ oral thin film (OTF) delivery system for various wellness products, such as CUREfilm Blue™ (sildenafil for erectile dysfunction), Vitamin D3, sugar-free electrolytes, and a melatonin sleep aid. CURE is in discussions with major distributors in Mexico and Latin America, aiming to expand its reach in the growing health and wellness market. This collaboration with Milagro Pharmaceuticals is expected to enhance CURE's production capabilities.
CURE Pharmaceutical Holdings (OTCQB: CURR) has announced a strategic partnership with Northern Response International to distribute the Seratopical Revolution® skin care line in Canada. This collaboration enables CURE to expand its market presence and brand portfolio internationally. The Seratopical line features plant-based formulations and a proprietary delivery system, endorsed by global icon Nicole Kidman. Northern Response will leverage its extensive distribution channels to promote this masstige brand, enhancing CURE’s reach in the lucrative beauty sector.
CURE Pharmaceutical Holding Corp. (OTC: CURR) announced the upcoming issuance of U.S. Patent No. 11,179,331 for its product CUREfilm Blue™, an oral soluble film containing sildenafil citrate, aimed at treating erectile dysfunction (ED). This innovative drug delivery method utilizes CURE's proprietary CUREfilm™ technology, enhancing patient experience with discreet and convenient administration. The erectile dysfunction drug market is projected to reach approximately USD$6.6 billion by 2025, with significant growth expected for sildenafil.
CURE Pharmaceutical Holding Corp. (OTC: CURR) reported a remarkable 700% revenue increase to $2.1 million for Q2 2021, with gross profit rising 676% to $1.31 million. The net loss decreased significantly to $3.27 million from a loss of $13.47 million year-over-year. Key developments include CVS's upcoming launch of the Seratopical Revolution skincare line, ISO 9001 certification for its facility, successful initial clinical trials of CUREfilm Blue™, and a partnership with Biopharmaceutical Research Company to create cannabis-based medical products for Veterans.